Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cialis Sheds Alpha Blocker Contraindication

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly/Icos’ erectile dysfunction agent revises labeling to include a new subsection on alpha blockers within the Precautions section, but no contraindication. Schering Plough/GlaxoSmithKline’s Levitra is now the only PDE5 inhibitor with the contraindication.

You may also be interested in...



Schering/GSK Levitra Labeling Drops Alpha Blocker Contraindication

Alpha blocker/PDE-5 inhibitor contraindication in vardenafil labeling is downgraded to precaution; the language is identical to a recent revision for Lilly’s Cialis. References on concomitant use with alpha blockers are now on par with Cialis and Pfizer’s Viagra.

Schering/GSK Levitra Labeling Drops Alpha Blocker Contraindication

Alpha blocker/PDE-5 inhibitor contraindication in vardenafil labeling is downgraded to precaution; the language is identical to a recent revision for Lilly’s Cialis. References on concomitant use with alpha blockers are now on par with Cialis and Pfizer’s Viagra.

Bayer Seeking Levitra Label Without Alpha Blocker Contraindication

Second quarter sales for Levitra were lower than expected, hampered by a slow erectile dysfunction market, the company says. Bayer remains optimistic about long-term Levitra sales growth despite competition from Pfizer and Lilly.

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel